TLE2 and urinary bladder cancer: Further analysis of the TCGA bladder cancer cohort according to clinical stage showed that lower ANLN (n = 77 with low expression, n = 41 with high expression; median survival, 23.43 vs. 19.66 months, and p = 0.0397) and TLE2 (n = 67 with low expression, n = 51 with high expression; median survival, 17.94 vs. 20.37 months, and p = 0.0100) expression in the pT2 subgroup could be attributed to a good and poor prognosis of OS, respectively (Figure 2e,f).